14 results about "Zika virus" patented technology

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

The application discloses a recombinant adenovirus shuttle plasmid and a preparation method thereof, a recombinant adenovirus and application thereof, and a Zika virus recombinant adenovirus plasmid, and belongs to the field of biological medicines. The Zika virus recombinant adenovirus shuttle plasmid provided by the application takes pShuttle as a carrier, carries a Zika virus E protein mutant gene, and the 5' end of the Zika virus E protein mutant gene is connected with a signal peptide gene; the 5' end of the signal peptide gene is connected with a Kozak sequence; and the 5' end of the Kozak sequence is connected with an enzyme cutting site 1. The recombinant shuttle plasmid, the recombinant plasmid and the recombinant adenovirus provided by the application can be applied to the preparation of a Zika virus adenovirus vaccine, and have wide development and application prospects.

The present invention pertains to compounds that inhibit Flavivirus NS2B-NS3 proteases and are potent and selective inhibitors of the West Nile virus and Zika virus. The compounds of the invention can be used alone or in combination with other agents to treat infections caused by these viruses. Additionally, the invention relates to pharmaceutical compositions containing these compounds.

The present invention relates to a pharmaceutical composition for prevention or treatment breast cancer, containing a chimeric Zika virus obtained through breast cancer cell passages as an active ingredient.

The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.

Provided herein are compositions including a binding reagent for a Zika virus (ZIKV) epitope, pharmaceutical compositions including such binding reagents, and methods of detecting ZIKV binding antibodies and ZIKV neutralizing antibodies in patients.

Attenuated forms of virulent Zika virus and Hepatitis C virus are provided. Vaccine compositions comprising the attenuated virus and methods of eliciting a protective immune response in a subject by administering the vaccine compositions are also provided.

Provided in the present disclosure are a Zika / dengue vaccine and its application thereof. The present disclosure introduces a mutation into the E-protein FL fusion region of the Zika virus or dengue virus. Antigens with said mutations are unable to bind to antibodies that causes ADE. After immunization with the vaccine of the present disclosure acquired from the said antigens, production of FL epitope-induced antibodies can be prevented, thereby reducing or eliminating the ADE effect.

This invention discloses a semi-quantitative RT-LAMP method and kit for viral nucleic acid detection based on dispensed lyophilized microspheres and a multi-channel microfluidic chip. The method includes: designing two independent LAMP primer sets (P1 and P2) for each of the SARS-CoV-2 Omicron strain N gene, Zika virus NS5 gene, H1N1 influenza virus M1 gene, and H3N2 influenza virus NP gene; preparing two independent types of lyophilized microspheres by independently mixing RT-LAMP premix containing Bst DNA polymerase and other components with LAMP primer mixture and a lyophilization protectant; and using an N-channel microfluidic chip to perform serial dilutions and parallel RT-LAMP amplification of the same sample, determining the concentration of viral nucleic acid in the sample by the positive / negative inflection points of each channel. This invention is simple to operate, requires no equipment such as a real-time PCR instrument, and is suitable for rapid virus detection in various scenarios.

Provided herein are compounds and methods for treating or preventing Zika virus infection. For example, compounds of Formula (I): wherein the variable substituents are as described herein. (I)

To provide specific N4-hydroxycytidine derivatives, pharmaceutical compositions, and related methods. [Solution] In certain embodiments, this disclosure relates to the treatment or prevention of viral infections such as Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika virus infection, by the compounds disclosed. In certain embodiments, this disclosure intends to provide derivatives of the compounds disclosed herein, such as compounds containing one or more of the same or different substituents.

The application discloses a Zika virus genomic fragment armoured RNA reference substance and a preparation method and application thereof, and is characterized in that the following steps are included: (1) constructing a prokaryotic expression skeleton vector pACYCAR (2) cloning a ZKV genomic fragment ZKA (nt81-2350) (3) constructing a prokaryotic expression vector pACYCAR-ZKA (4) inducing expression of armoured RNA (5) purifying the armoured RNA. The application solves the technical problems of high biological safety risk, poor stability and insufficient gene fragment coverage of existing ZKV nucleic acid detection reference substances. The application fills the blank of the lack of high-quality reference substances for ZKV detection.